efficacy

Prognostic factors and outcomes of cancer patients with COVID-19 4:50
Prognostic factors and outcomes of cancer patients with COVID-19
Petros Grivas • 11 Jun 2021
De-escalating chemo-radiotherapy in locally advanced HPV+ oropharynx cancer 8:10
De-escalating chemo-radiotherapy in locally advanced HPV+ oropharynx cancer
Marshall R. Posner • 16 Jun 2021
The future of NSCLC treatment 3:28
The future of NSCLC treatment
Benjamin Besse • 7 Jun 2021
JAVELIN Bladder 100: duration of treatment-free interval 3:13
JAVELIN Bladder 100: duration of treatment-free interval
Srikala Sridhar • 8 Jun 2021
Lung cancer updates at ASCO 2021 2:00
Lung cancer updates at ASCO 2021
David Spigel • 26 May 2021
ARAMIS: darolutamide in patients with nmCRPC 2:46
ARAMIS: darolutamide in patients with nmCRPC
Neal Shore • 28 May 2021
CheckMate 238: nivolumab versus ipilimumab in stage III melanoma 1:59
CheckMate 238: nivolumab versus ipilimumab in stage III melanoma
James Larkin • 26 May 2021
Patritumab deruxtecan in patients with EGFR-mutant NSCLC 1:52
Patritumab deruxtecan in patients with EGFR-mutant NSCLC
Pasi Jänne • 1 Jun 2021
ESMO Breast 2021: What to expect? 1:54
ESMO Breast 2021: What to expect?
Paolo Tarantino • 27 Apr 2021
Vismodegib in basal cell carcinoma 2:48
Vismodegib in basal cell carcinoma
Piotr Rutkowski • 23 Feb 2021
Neoadjuvant targeted therapy in BRAF V600 mutated melanoma 2:40
Neoadjuvant targeted therapy in BRAF V600 mutated melanoma
Piotr Rutkowski • 23 Feb 2021
Cemiplimab in advanced BCC 2:36
Cemiplimab in advanced BCC
Ketty Peris • 23 Apr 2021
ZENITH20: Poziotinib efficacy and safety in NSCLC 1:58
ZENITH20: Poziotinib efficacy and safety in NSCLC
Adrian Sacher • 15 Mar 2021
PSMA targeted CAR-T therapy for prostate cancer 1:58
PSMA targeted CAR-T therapy for prostate cancer
Bruce Levine • 11 Mar 2021
Efficacy and safety of MEDI1191 in patients with solid tumors and superficial lesions 5:14
Efficacy and safety of MEDI1191 in patients with solid tumors and superficial lesions
Omid Hamid • 12 Mar 2021
Cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer 1:37
Cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
Cedric Pobel • 13 Mar 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals